Medical/Pharmaceuticals
Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors
HONG KONG, Feb. 9, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the start of a Phase I clinical trial for evaluation of the safety, tolerability and anti-...
2022-02-09 17:12
2347
Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors
HONG KONG, Feb. 9, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the start of a Phase I clinical trial for evaluation of the safety, tolerability and anti-...
2022-02-09 17:10
2840
Hummingbird Bioscience Publishes Preclinical Data Demonstrating Therapeutic Potential of HMBD-002 in VISTA-expressing Cancers
HOUSTON and SINGAPORE, Feb. 9, 2022 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, today announced the publication of preclinical data for HMBD-002, a nov...
2022-02-09 17:00
2381
Glenmark and SaNOtize announce positive Results from Phase 3 Clinical Trial of NONS (FabiSpray®) in Non-Hospitalized Adult Indian Patients with COVID-19
* Phase 3 trial in India met the key endpoints and demonstrated reduction of viral load of 94% in 24 hours and 99% in 48 hours. * NONS was safe and well tolerated in COVID-19 patients. * Glenmark received manufacturing and marketing approval from India's drug regulator for Nitric Oxide Nasal...
2022-02-09 15:47
3499
COLOPLAST SINGAPORE LAUNCHES SENSURA MIO(R), A PRODUCT MADE WITH THE LATEST TECHNOLOGY FOR OSTOMY AND STOMA CARE
* SenSura® Mio features BodyFit technology, an elastic adhesive technology fit for all peristomal body profiles. SINGAPORE, Feb. 9, 2022 /PRNewswire/ -- Coloplast, one of the world's leading manufacturers of stoma care products launches its latest product innovation, the SenSura®Mio in Singapor...
2022-02-09 12:44
2934
Luye Pharma Grants Laboratorio LIBRA Exclusive Marketing Rights for Seroquel and Seroquel XR in Chile
SHANGHAI, Feb. 9, 2022 /PRNewswire/ -- Luye Pharma Group announced today that it has entered into an agreement with Laboratorio LIBRA, under which the company grants Laboratorio LIBRA the exclusive rights to market its innovative CNS (central nervous system) drugs Seroquel (quetiapine fumarate, i...
2022-02-09 11:57
2725
CStone announced new drug approval of China's first IDH1 inhibitor TIBSOVO® (ivosidenib tablets) as a new precision therapy for patients with acute myeloid leukemia
* TIBSOVO®, a first-in-class drug, is approved for adult patients with relapsed/refractory acute myeloid leukemia (R/R AML) who have a susceptible IDH1 mutation * Clinical study data showed that TIBSOVO® had robust clinical efficacy and a well-tolerated and manageable safety profile in Chines...
2022-02-09 11:53
5613
Bugworks Research Inc. secures US$18M Series B1 Funding from Reputed Global Investor Syndicate (The EU, UK, Japan, South Africa & India), led by Lightrock India
This Funding will advance highly differentiated assets in the dual areas of Antimicrobial Resistance (AMR) and Immuno-Oncology (IO) BANGALORE, India, SARATOGA, Calif. and ADELAIDE, Australia, Feb. 9, 2022 /PRNewswire/ -- Bugworks Research, a clinical stage multi-indication therapeutics company, ...
2022-02-09 10:00
11289
Bactiguard presents focused growth strategy and sets new long-term financial targets
STOCKHOLM, Feb. 9, 2022 /PRNewswire/ -- Bactiguard presents new long-term financial targets in connection with the year-end report for 2021. The new financial targets relate to growth and profitability, with annual revenues of at least1 billion SEK and annual EBITDA of at least 400 million SEK in...
2022-02-09 07:27
2744
First Proton Therapy Treatment Delivered in Southeast Asia at Her Royal Highness Princess Maha Chakri Sirindhorn Proton Center, Thailand
BANGKOK, Feb. 9, 2022 /PRNewswire/ -- Varian, a Siemens Healthineers company, today announced that Her Royal Highness Princess Maha Chakri Sirindhorn Proton Center has begun treating patients with its new Varian ProBeam® proton therapy system, the first of its kind inThailand and Southeast Asia. ...
2022-02-09 05:15
5811
Bactiguard and Zimmer Biomet expand global license partnership
STOCKHOLM, Feb. 9, 2022 /PRNewswire/ -- Bactiguard and Zimmer Biomet have today agreed to expand the global license partnership, that was initiated in 2019, to cover multiple product segments. The extended exclusive license agreement covers implants for joint reconstruction (hips and knees), spo...
2022-02-09 04:10
2378
Cambrex Recognized with 2022 CMO Leadership Awards for the 8th Consecutive Year
EAST RUTHERFORD, N.J., Feb. 8, 2022 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), announced today that it has been recognized by the annual CMO (Contract Manufacturing Organization) Leadership Awards in the categories of Quality and Service....
2022-02-08 22:30
4060
WuXi Biologics Statement
SHANGHAI, Feb. 8, 2022 /PRNewswire/ -- We have been made aware of a recent U.S. Commerce Department announcement that two WuXi Biologics (Cayman) subsidiaries inShanghai and Wuxi will be added to the department's "Unverified List" (UVL) on February 8, 2022. We understand that the reason for this a...
2022-02-08 11:08
4268
Bijoyesh Mookerjee, M.D. named Chief Medical Officer, Oncology for Simcere Pharmaceuticals
NANJING, China, Feb. 7, 2022 /PRNewswire/ -- Simcere is thrilled to announce Bijoyesh Mookerjee, M.D., as our Chief Medical Officer, Oncology, of Simcere Pharmaceutical Group. Bijoyesh will be responsible for Simcere's oncology clinical pipeline strategy and development, enhancing our global res...
2022-02-08 10:01
2607
Singapore-Johor VTL resumes with COVID-19 test results issued by Jebhealth
SINGAPORE, Feb. 8, 2022 /PRNewswire/ -- With the resumption of the land VTL betweenSingapore and Johor Bahru on Jan 21, about 2,000 travellers are expected to cross the causeway each day, in hope that we can eventually scale up to the normal 300,000 daily commutes. Many would be meeting their lov...
2022-02-08 07:00
4473
Bridge Biotherapeutics and Scripps Research Launch Research Collaboration to Develop Discovery Platform and Novel Covalent Probes Based on Chemical Biology and Chemoproteomics
* Two-year research collaboration to develop new reactive group chemistries targeting non-cysteine amino acids to expand druggable binding sites and identify novel targets in oncology and immunology * Collaborators at Scripps are pioneers in the field of chemical biology and chemistry SEONGNA...
2022-02-08 06:00
2516
IonOpticks enters OEM partnership with Bruker that sets a new standard for mass spectrometry-based research
MELBOURNE, Australia, Feb. 7, 2022 /PRNewswire/ -- Premium manufacturer of chromatography for proteomics applications, IonOpticks, has entered an OEM partnership with the Bruker Corporation (Nasdaq: BRKR), allowing Bruker to expand their portfolio of 4D-Proteomics solutions with the release of th...
2022-02-08 00:01
2747
Covaris AFA-energetics™ Enables True Automated Total Nucleic Acid Extraction and Purification Workflows from FFPE Tissues
A fully automated, high-throughput deparaffinization and total Nucleic Acids extraction and purification kit for FFPE samples WOBURN, Mass., Feb. 7, 2022 /PRNewswire/ -- Covaris, LLC ("Covaris" or "the Company"), a manufacturer of advanced tools enabling life science innovations, announced the l...
2022-02-07 23:00
3984
US FDA Study May Proceed letter for Clarity's Cu-64 SAR-bisPSMA trial in prostate cancer
SYDNEY, Feb. 7, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has received a confirmation from the US Food and Drug Adm...
2022-02-07 22:08
2914
KAZIA THERAPEUTICS TO PRESENT AT BIO CEO CONFERENCE
SYDNEY, Feb. 7, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, DrJames Garner, will be presenting at the BIO CEO Conference, to be held in person and virtually inNew York, NY, from 14-17 Febr...
2022-02-07 21:00
4032
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 273 media titles]
2026-10-09 13:21The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth
[Picked up by 263 media titles]
2026-10-05 13:24